Novel Direct-to-Brain Intracerebroventricular Stem Cell Phase 1 Trial Shows Safety and Exciting Results in Alzheimer’s
Six-Patient Trial Shows Significant Alzheimer’s CSF Biomarker Changes up to 52 Weeks; FDA Fast Track Granted, Phase 2 Planned for December. NEWPORT BEACH, CA, UNITED STATES, November 18, 2026 /EINPresswire.com/ -- Regeneration Biomedical, Inc., a …